COFEPRIS, CONBIOÉTICA Detail Rollout of Clinical Trial Reform

COFEPRIS and CONBIOÉTICA briefed 435 representatives of Mexico's clinical research sector on the January 2026 General Health Law reform, which seeks to streamline protocol submission and review without reducing ethical or scientific requirements. The initiative follows separate reductions in COFEPRIS approval timelines from 120 to 30 days. 

The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) and the National Bioethics Commission (CONBIOÉTICA) convened representatives of Mexico's clinical research ecosystem to explain how reforms to the General Health Law, in force since January 2026, will be applied in practice. The session focused on reducing friction in protocol submissions while preserving the ethical rigor required for clinical trials.  

Víctor Borja, Federal Commissioner, COFEPRIS, told attendees that regulators and the regulated sector belong to the same ecosystem and share an interest in strengthening clinical research in Mexico. He said training sessions should help participants understand the legal changes, align their internal processes accordingly, and contribute to making those processes more efficient, while keeping ethical evaluation at the center of the system. COFEPRIS has stressed that regulatory efficiency cannot be measured only by shorter timelines. 

It also depends on applications arriving correctly integrated, on committees understanding their respective responsibilities, and on institutions applying consistent review criteria. Better coordination among sponsors, research centers, ethics committees, and authorities, the agency argues, could cut the returns, clarification requests, and delays that stem from incomplete files or differing interpretations of requirements.  

The changes trace back to a decree published in the Federal Official Gazette on Jan. 15, 2026, which amended, added, and repealed several provisions of the General Health Law, including Articles 41 Bis and 98. Patricio Santillan, National Commissioner of Bioethics, said the administration had identified bottlenecks slowing the drafting, review, and approval of clinical research protocols, and that those difficulties drove the legislative changes. Since January, COFEPRIS and CONBIOÉTICA have worked on implementation through coordination and training activities such as this one.

Santillan said that the reform adjusts procedures without altering the substance of clinical research, adding that trials still need to meet scientific, methodological, and ethical standards, and must be oriented toward benefiting Mexican society. Ethical review, he noted, continues to weigh participant protection, the balance between risks and benefits, the adequacy of information provided for informed consent, and the appropriateness of study design, while regulatory evaluation continues to verify technical grounding and compliance with safety, efficacy, and quality standards.  

The reform builds on a broader push to modernize Mexico's health-research framework; COFEPRIS has separately reported cutting clinical trial approval times from roughly 120 to 30 days, a shift MBN described as having direct implications for pharma investment, CROs, and medtech companies evaluating Latin America. The January reform itself extended well beyond clinical trials, also introducing an outright ban on vaping devices and formally recognizing digital health under Mexican law.

COFEPRIS and CONBIOÉTICA linked the reform to three broader goals: strengthening clinical research, attracting investment to the health sector, and expanding patient access to innovative therapies. Predictable review timelines and clearly defined requirements could make Mexico more competitive as a destination for clinical studies and help research centers plan projects with less regulatory uncertainty.  

However, a rise in the number of studies conducted does not automatically translate into broader access to treatments, since participation in clinical research remains subject to inclusion and exclusion criteria, the availability of research centers, protocol conditions, and decisions made by investigating teams. 

New treatments also require multiple additional stages of evaluation before wider incorporation into patient care, meaning the link between regulatory agility, investment, and access should be treated as an institutional expectation still requiring follow-up rather than a guaranteed outcome.

The information presented at the session did not include new evaluation deadlines, specific documentary requirements, or indicators for measuring the announced efficiency gains, leaving the operational scope of the reform dependent on its implementation and on complementary provisions still to come.  

Officials said future assessments will need to determine whether the new rules shorten response times, improve the quality of submitted dossiers, and reduce requests for additional information, all without compromising the independence of ethics committees or the protection of trial participants.  

The central challenge going forward, according to the agencies, is balancing faster processing of applications with the rigor required for protocol evaluation, since efficiency has value only if it supports quality research rather than weakening essential controls. The meeting represents a step toward preparing that implementation; whether it succeeds will depend on translating the legal changes into verifiable results for research centers, regulators, and patients.